| 李月.脾氨肽联合布地奈德治疗过敏性鼻炎患儿的效果及对外周血Th17/Treg平衡和相关细胞因子水平的影响[J].安徽医药,待发表. |
| 脾氨肽联合布地奈德治疗过敏性鼻炎患儿的效果及对外周血Th17/Treg平衡和相关细胞因子水平的影响 |
|
| 投稿时间：2023-09-01 录用日期：2023-11-29 |
| DOI： |
| 中文关键词: 关键词：脾氨肽 布地奈德 过敏性鼻炎 辅助性T细胞17 调节性T细胞 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 331 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要 目的：观察脾氨肽联合布地奈德治疗过敏性鼻炎患儿的效果并分析其对外周血辅助性T细胞17（Th17）/调节性T细胞（Treg）平衡及相关细胞因子水平的影响。方法：选取2020年10月～2021年10月本院收治的126例过敏性鼻炎患儿作为研究对象，按随机数字表分为2组。对照组63例给予布地奈德鼻喷雾剂治疗，联合组63例采用脾氨肽口服溶液联合布地奈德鼻喷雾剂治疗，均治疗3个月。观察治疗前后临床症状变化、Th17/Treg、血清白细胞介素-6（IL-6）、白细胞介素-17（IL-17）、转化生长因子-β1（TGF-β1）水平及疗效，对比2组不良反应发生情况。结果：治疗后，2组临床症状评分均降低（P＜0.05），但联合组均低于对照组（P＜0.05）；治疗后，2组Th17比例、Th17/Treg、IL-6、IL-17水平均降低（P＜0.05），Treg比例、TGF-β1水平均升高（P＜0.05），但联合组Th17细胞比例、Th17/Treg、IL-6、IL-17水平[（52.64±7.04）%、（1.31±0.26）、（110.44±11.48）ng/L、（26.26±4.54）ng/L]均低于对照组[（55.37±7.52）%、（1.63±0.31）、（131.37±13.04）ng/L、（30.18±5.02）ng/L]；联合组Treg细胞比例、TGF-β1水平[（40.06±5.14）%、（206.47±35.24）ng/L]均高于对照组[（37.18±4.82）%、（150.39±26.53）ng/L]，差异均有统计学意义（P＜0.05）；联合组总有效率为93.65%，高于对照组的80.95%（P＜0.05）；2组不良反应发生情况无明显差异（P＞0.05）。结论：脾氨肽联合布地奈德治疗有助于缓解过敏性鼻炎患儿症状，调节外周血Th17/Treg平衡和相关细胞因子水平，疗效好且安全。 |
| 英文摘要: |
| Abstract Objective: To observe the efficacy of Spleen Aminopeptide combined with budesonide in the treatment of allergic rhinitis in children and analyze its impact on the balance of peripheral blood helper T cell 17 (Th17) / regulatory T cell (Treg) and related cytokine levels. Methods: 126 children with allergic rhinitis treated in our hospital from October 2020 to October 2021 were randomly divided into two groups. 63 cases in the control group were treated with budesonide nasal spray, while 63 cases in the combined group were treated with Spleen Aminopeptide Oral Solution Combined with budesonide nasal spray, and both groups were treated for 3 months. The changes of clinical symptoms, Th17/Treg, serum interleukin-6 (IL-6), interleukin-17 (IL-17) and transforming growth factor-β1(TGF-β1) level were observed before and after treatment and curative effect. The adverse reactions of the two groups were compared. Results: After treatment, the clinical symptom scores of two groups were decreased (P < 0.05), but the combined group were lower than the control group (P < 0.05). After treatment, the proportion of Th17, Th17/Treg, and the levels of IL-6 and IL-17 in two groups were decreased (P < 0.05), while the proportion of Treg and the level of TGF-β1 were increased (P < 0.05). The proportion of Th17 cells, Th17/Treg, and the levels of IL-6 and IL-17 in the combination group were[ (52.64±7.04) %, (1.31±0.26), (110.44±11.48) ng/L and (26.26±4.54) ng/L], which were lower than those in control group [(55.37±7.52) %, (1.63±0.31), (131.37±13.04) ng/L, (30.18±5.02) ng/L]. The proportion of Treg cells and the level of TGF-β1 in combination group were [(40.06±5.14) % and (206.47±35.24) ng/L], which were higher than those in control group [(37.18±4.82) % and (150.39±26.53) ng/L], with statistical significance (P < 0.05). The total effective rate of the combined group was 93.65%, higher than 80.95% of the control group (P < 0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P > 0.05). Conclusion: The treatment of spleen peptide combined with budesonide is helpful to alleviate the symptoms of children with allergic rhinitis, regulate the balance of Th17/Treg in peripheral blood and the level of related cytokines, which is effective and safe. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
